Navigation Links
Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
Date:9/18/2012

CAMBRIDGE, Mass., Sept. 18, 2012 /PRNewswire/ -- Eutropics Pharmaceuticals has signed a contract with the National Cancer Institute through the Small Business Initiative Research (NCI-SBIR) program to develop its proprietary BH3 profiling diagnostic assay for personalized medicine approaches in Acute Myelogenous Leukemia (AML) patient management. The assay provides a biomarker/ diagnostic to help guide the use of several approved therapies for multiple cancer indications and is being tested as a companion test for experimental therapies currently in development. The biomarker provides a unique, functional understanding of cancer cells that indicates if they are capable of responding to certain treatments. This understanding will be important in deciding when to use, or to avoid certain therapies in treating patients. The work funded by this contract will validate early results that indicate the predictive utility of the assay. The technology also provides insights that are useful in the pre-clinical development of new therapeutics.  Eutropics is currently working with several leading cancer centers to validate the clinical utility of the assay and expand these studies into clinical trials with pharmaceutical partners in the next stage of the study.

The use of BH3 profiling as a novel diagnostic approach in personalized medicine is consistent with the July 2011 roadmap announcement made by the FDA calling for companion tests that will improve treatment efficacies by selecting appropriate use of targeted oncology therapies based on predictive molecular discriminators.  "This award confirms our approach to providing such a test and positions Eutropics to move the technology forward, empowering oncologists with valuable information for providing the most effective care to their patients," said Michael Cardone, Chief Executive Officer at Eutropics.

"There is a very good likelihood that this BH3 profiling technology will provide an important guiding tool for treating AML," said Dr. Michael Andreeff, Chief of Molecular Hematology at MD Anderson Cancer Center and scientific advisor to Eutropics. "We are all looking forward to its validation in the clinical studies proposed in this contract," he added.

About BH3 profiling
In the area of cancer treatment, understanding, detecting, and controlling mitochondrial function is a critical area of focus. It has become clear over the past twenty years of apoptosis research that events occurring at the mitochondrial surface determine the ability of the cancer cell to respond to apoptosis-inducing cancer therapy. Mitochondria therefore represent a critical node for understanding how to selectively kill cancer cells while preserving non-cancer cells. BH3 profiling can be used to determine if the mitochondria in a cancer cell are preset to commit a cell to death in response to upstream signaling. This understanding identifies if a cancer cell will or will not respond to apoptosis signals. By this understanding, one can predict responses to therapies that either initiate signals upstream of the mitochondria or directly target proteins which regulate apoptosis at the mitochondrial surface.  To date, the BH3 profiling assay has proven highly effective at identifying when certain apoptosis-inducing therapies will or will not be effective, both in cancer cells in vitro and in cancer patients.

About Eutropics Pharmaceuticals
Eutropics Pharmaceuticals is using a new biomarker/companion diagnostic to help guide the development and use of cancer therapies.  The biomarker provides a unique understanding of cancer cells that is important in the pre-clinical development of experimental drugs and will be important in the later stages of their development, including the development of Eutropics' first in class anti-cancer therapeutic compound that targets the apoptosis regulating protein Mcl-1. BH3 profiling also has utility as a predictive diagnostic assay for therapies currently in use to treat multiple myeloma, AML, and CLL, and will have wider oncology applications. The BH3 profiling technology seeks to displace current treatment paradigms by developing predictive clinical tests that may be used to identify when a particular therapy is or is not likely to be effective in a particular patient. This personalized medicine approach will result in more effective treatments and reduce unnecessary suffering.  The company is supported by private investors, grants and contracts from the National Cancer Institute (NCI), and funding from the State of Massachusetts.


'/>"/>
SOURCE Eutropics Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
(Date:4/28/2016)... 28, 2016 New market ... is a report that provides an overview of ... pipelines by identifying new targets and MOAs to ... Profiles discussed in this H1 2016 Osteoarthritis Pipeline ... AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios ...
Breaking Medicine Technology:
(Date:4/30/2016)... Indianapolis, Indiana (PRWEB) , ... April 30, 2016 , ... ... USA Wrestling as they go for gold in Rio. Under the care of ... including two golds! , In an unprecedented showing, Maximized Living is sending the largest ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... the deadliest type of skin cancer. Although only about 1 percent of skin cancer cases ... 10,000 people are expected to die of melanoma this year. The risk increases with age, ... most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies may give ...
Breaking Medicine News(10 mins):